Code intelligence

FDA-NDA209988 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA209988.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

—

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: FUROSCIX (FUROSEMIDE INJECTION 80 MG/ 10 ML) — Type 3 - New Dosage Form

Policy FDA-NDA209988 · Cardiology

High

Furoscix (furosemide 80 mg/10 mL subcutaneous injection) received FDA approval in October 2022 as a new dosage form of furosemide for subcutaneous administration, designated under Part B given its inj

View alert

Audit documentation

Building an audit file that includes FDA-NDA209988?

The Tripwire Audit Pack exports 12 months of Cardiology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Cardiology audit pack — $349One-time purchase · not a subscription